Chemed Corporation announced a 10.6% revenue increase to $690.9 million for Q3 2026, with adjusted diluted EPS rising 28.1% to $6.75. Growth was led by VITAS Healthcare, with a 12.2% rise in net patient revenue and a 9.4% increase in average daily census, and Roto-Rooter, which saw a 7.5% revenue increase despite a slight decline in adjusted EBITDA. The company repurchased shares and expects to meet or exceed its full-year 2026 adjusted EPS guidance. Chemed also re-acquired multiple franchise territories for Roto-Rooter in California, expanding its market presence.
Chemed Corporation's third-quarter 2026 results provide context for readers interested in healthcare. As of Oct 28, 2026 03:11 WIB, among 150 priced US health-sector stocks tradable on Pluang, 88 rose and 62 fell. Notable movers include BFLY at USD 7.38 with a 10.81% increase, IBRX at USD 8.61 with a 10.24% rise and 100% buy order activity, and TWST at USD 159.95 with a 10.12% gain. The most notable figure is BFLY's 10.81% price increase.
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strate...
argenx SE announced it will stop its Phase 3 UNITY study of efgartigimod subcutaneous for moderate-to-severe Sjögren's disease after an independent committee found the trial unlikely to meet its primary goal. This decision caused the company's stock ...
Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a sharp stock price drop triggered by a new U.S. federal strategy targeting the dialysis market. The Department of Health and Human Services announced a plan to incre...
Pomerantz LLP is investigating ClearPoint Neuro and its executives for possible securities fraud following a significant stock price drop. The decline occurred after ClearPoint's partner, uniQure, announced that their Huntington's disease treatment f...
